The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty 100 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma responded to NSE's clarification request about a Moneycontrol news article reporting that US President Trump sent letters to 17 global pharmaceutical companies demanding Most Favoured Nation pricing for medicines in the US. The company confirmed that Sun Pharma is NOT among the recipients of this letter. The management stated there is no company-specific development or material event that would explain the recent decline in the share price, and no legal proceedings related to the company were mentioned in the news report. Since Sun Pharma is not a party to the action described, the company declined to comment further on the broader sector development.
For shareholders, this clarifies that the stock price fall was a sector-wide reaction to Trump's drug pricing move and not due to anything company-specific. Sun Pharma is not directly targeted, which removes one layer of near-term uncertainty, though broader pharma sector sentiment may remain volatile on US drug pricing policy news.